J. Bauman, K. Eaton, and R. Martins, Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab, Archives of Dermatology, vol.143, issue.7, pp.889-92, 2007.
DOI : 10.1001/archderm.143.7.889

M. Alam and D. Ratner, Cutaneous Squamous-Cell Carcinoma, New England Journal of Medicine, vol.344, issue.13, pp.975-83, 2001.
DOI : 10.1056/NEJM200103293441306

H. Sadek, N. Azli, J. Wendling, E. Cvitkovic, M. Rahal et al., Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin, Cancer, vol.8, issue.8, pp.1692-1698, 1990.
DOI : 10.1002/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y

T. Khansur and A. Kennedy, Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin, Cancer, vol.4, issue.8, pp.2030-2032, 1991.
DOI : 10.1002/1097-0142(19910415)67:8<2030::AID-CNCR2820670803>3.0.CO;2-K

D. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies. Critical reviews in oncology, hematology, vol.19, issue.3, pp.183-232, 1995.

P. Dziunycz, Z. Lazarova, N. Duncan, S. Wong, M. Neuburg et al., EGFRvIII Expression in Squamous Cell Carcinoma of the Skin, JAMA Dermatology, vol.149, issue.10, pp.1240-1242, 2013.
DOI : 10.1001/jamadermatol.2013.5230

E. Van-cutsem, C. Kohne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009.
DOI : 10.1056/NEJMoa0805019

J. Bourhis, F. Rivera, R. Mesia, A. Awada, L. Geoffrois et al., Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Journal of Clinical Oncology, vol.24, issue.18, pp.2866-72, 2006.
DOI : 10.1200/JCO.2005.04.3547

J. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki et al., Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer, New England Journal of Medicine, vol.359, issue.11, pp.1116-1143, 2008.
DOI : 10.1056/NEJMoa0802656

J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin et al., Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.354, issue.6, pp.567-78, 2006.
DOI : 10.1056/NEJMoa053422

W. De-roock, B. Claes, D. Bernasconi, D. Schutter, J. Biesmans et al., PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis K-ras mutations and benefit from cetuximab in advanced colorectal cancer, The Lancet Oncology, vol.11359, issue.1217, pp.753-621757, 2008.

E. Maubec, P. Petrow, I. Scheer-senyarich, P. Duvillard, L. Lacroix et al., Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin, Journal of Clinical Oncology, vol.29, issue.25, pp.3419-3445, 2011.
DOI : 10.1200/JCO.2010.34.1735

D. Giacchero, J. Barriere, K. Benezery, B. Guillot, C. Dutriaux et al., Efficacy of Cetuximab for Unresectable or Advanced Cutaneous Squamous Cell Carcinoma ??? A Report of Eight Cases, Clinical Oncology, vol.23, issue.10, pp.716-724, 2011.
DOI : 10.1016/j.clon.2011.07.007

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-221, 2000.
DOI : 10.1093/jnci/91.6.523

J. Hecht, E. Mitchell, M. Neubauer, H. Burris, P. Swanson et al., Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.2616, issue.177, pp.374-92205, 2008.

J. Tol, J. Dijkstra, M. Klomp, S. Teerenstra, M. Dommerholt et al., Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab, European Journal of Cancer, vol.46, issue.11, pp.1997-2009, 2010.
DOI : 10.1016/j.ejca.2010.03.036

S. Forbes, D. Beare, P. Gunasekaran, K. Leung, N. Bindal et al., COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Research, vol.29, issue.D1, pp.805-816, 2015.
DOI : 10.1093/bioinformatics/btt182

R. Al-rohil, A. Tarasen, J. Carlson, K. Wang, A. Johnson et al., Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort, Cancer. Experimental dermatology, vol.12220, issue.210, pp.249-57848, 2011.

K. Ridd and B. Bastian, Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma. The Journal of investigative dermatology, pp.901-904, 2010.

P. Uribe, S. Gonzalez, P. Kanellou, D. Spandidos, W. Pierceall et al., Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathology, research and practice Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. The British journal of dermatology Ras gene mutation and amplification in human nonmelanoma skin cancers, Molecular carcinogenesis, vol.2071624, issue.253, pp.337-42325, 1991.

C. Pickering, J. Zhou, J. Lee, J. Drummond, S. Peng et al., Mutational landscape of aggressive cutaneous squamous cell carcinoma Clinical cancer research : an official journal of the American Association for Cancer Research Panitumumab- FOLFOX4 treatment and RAS mutations in colorectal cancer, pp.6582-921023, 2013.

F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag et al., RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England journal of medicine Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.36628, issue.296, pp.207-15918, 2010.

M. Foote, M. Mcgrath, A. Guminski, B. Hughes, J. Meakin et al., Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma, Annals of Oncology, vol.354, issue.10, pp.2047-52, 2014.
DOI : 10.1056/NEJMoa053422

Y. Li, G. Hanna, A. Laga, R. Haddad, J. Lorch et al., Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, pp.1447-56, 2015.